Rewind: Roche returns to phase 2 after seeing post hoc signal in failed pivotal Huntington’s trialnews2022-01-18T10:37:22+00:00January 18th, 2022|FierceBiotech|
‘Shots on goal’ to ‘deterministic’ drug development: Flagship CEO, Moderna Chair Noubar Afeyan pens first annual letternews2022-01-14T15:33:14+00:00January 14th, 2022|FierceBiotech|
‘Shots on goal’ to ‘deterministic’ drug development: Flagship CEO, Moderna Chair Afeyan pens first annual letternews2022-01-14T15:33:14+00:00January 14th, 2022|FierceBiotech|
JPM 2022: Decentralized trials, broader service offerings and novel drugs key trends in the CRO spacenews2022-01-14T14:49:46+00:00January 14th, 2022|FierceBiotech|
FDA approval, global partnership on the agenda at Mithra as phase 3 menopause trials hit goals—with one blemish news2022-01-14T12:04:23+00:00January 14th, 2022|FierceBiotech|
EMA sets out plan to accelerate clinical trials, reduce administrative burdennews2022-01-14T10:47:54+00:00January 14th, 2022|FierceBiotech|
FDA denies Denali’s Takeda-partnered Alzheimer’s drug from entering clinicnews2022-01-13T14:04:23+00:00January 13th, 2022|FierceBiotech|
Sarepta, with pivotal data in sight, dumps Lysogene gene therapynews2022-01-13T13:27:33+00:00January 13th, 2022|FierceBiotech|
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for new colorectal cancer biomarkernews2022-01-13T13:25:22+00:00January 13th, 2022|FierceBiotech|
JPM22, Day 4: Galapagos plots rebound with M&A, new CEO; Gritstone hopes for new cancer biomarker; Vertex’s cystic fibrosis dominancenews2022-01-13T13:25:22+00:00January 13th, 2022|FierceBiotech|
